Parkinson's disease (PD) is a common neurodegenerative disorder with a poorly understood physiopathology and no established biomarkers for the diagnosis of early stages and for prediction of disease progression. Several neuroimaging biomarkers have been studied recently, but these are susceptible to several sources of variability related for instance to cohort selection or image analysis. In this context, an evaluation of the robustness of such biomarkers to variations in the data processing workflow is essential. This study is part of a larger project investigating the replicability of potential neuroimaging biomarkers of PD. Here, we attempt to fully reproduce (reimplementing the experiments with the same methods, including data collection from the same database) and replicate (different data and/or method) the models described in (Nguyen et al., 2021) to predict individual's PD current state and progression using demographic, clinical and neuroimaging features (fALFF and ReHo extracted from resting-state fMRI). We use the Parkinson's Progression Markers Initiative dataset (PPMI, ppmi-info.org), as in (Nguyen et al., 2021) and aim to reproduce the original cohort, imaging features and machine learning models as closely as possible using the information available in the paper and the code. We also investigated methodological variations in cohort selection, feature extraction pipelines and sets of input features. Different criteria were used to evaluate the reproduction attempt and compare the results with the original ones. Notably, we obtained significantly better than chance performance using the analysis pipeline closest to that in the original study (R2 > 0), which is consistent with its findings. In addition, we performed a partial reproduction using derived data provided by the authors of the original study, and we obtained results that were close to the original ones. The challenges encountered while attempting to reproduce (fully and partially) and replicating the original work are likely explained by the complexity of neuroimaging studies, in particular in clinical settings. We provide recommendations to further facilitate the reproducibility of such studies in the future.